-+ 0.00%
-+ 0.00%
-+ 0.00%

Ernexa Therapeutics Announces 1-For-15 Reverse Stock Split, Effective June 12, 2025

Benzinga·06/10/2025 13:31:21
Listen to the news

Ernexa Therapeutics (NASDAQ:ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced a reverse stock split of its issued and outstanding shares of common stock, par value $0.005 per share (the "Common Stock"), at a ratio of 1-for-15, effective June 12, 2025 at 12:01 a.m. Eastern Time. The Company's Common Stock is expected to begin trading on a split-adjusted basis when the market opens on June 12, 2025, under the existing trading symbol "ERNA."

The Company is effecting the reverse split to regain compliance with the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The new CUSIP number following the reverse stock split will be 114082 308.